ClinicalTrials.govpublic full text
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
non-small cell lung cancer, lung cancer, iiia-n2, neo-adjuvant treatment, egfr mutations, tyrosine kinase inhibitor, interventional, phase2, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 830215
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.